Q-omics provides the consensus-scored SCN2B profile across patient tissues and cancer cell-line models. SCN2B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, SCN2B is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, SCN2B RNA expression shows 24,973 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, KIRC, and GBM as cancer lineages where SCN2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCN2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCN2B survival associations across molecular data types. SCN2B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCN2B RNA expression–survival associations across cancer types. High SCN2B expression shows unfavorable associations in LIHC, BLCA and ACC, but favorable associations in LUAD, LGG and UCEC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for SCN2B RNA expression.
This table summarizes SCN2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SCN2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCN2B shows lower tumor expression in KIRC, KICH, COAD, KIRP, BLCA and LUAD. The KIRC box plot shows higher SCN2B RNA expression in normal versus tumor tissue (log2 FC = −1.215, t-test p < 0.001).
This table shows molecular features associated with SCN2B in patient tissues and cancer cell lines. In patient samples, SCN2B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SCN2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
